Retatrutide 40 mg Multi-Dose Injection Pen

Retatrutide 40 mg Multi-Dose Pen

Retatrutide 40 mg Multi-Dose Pen

A pre-filled multi-dose pen containing 40 mg of retatrutide. Retatrutide is an investigational triple agonist that activates the GIP, GLP-1 and glucagon receptor pathways.

It is currently being investigated in Phase 3 clinical research across obesity, type 2 diabetes and several metabolic and cardiovascular-related conditions.

Product Details

• Compound: Retatrutide
• Total strength: 40 mg
• Concentration: 8 mg / 0.6 mL
• Format: Pre-filled multi-dose pen
• Presentation: Purple and white packaging

What is Retatrutide?

Retatrutide is a single peptide molecule designed to activate three hormonal receptor pathways:

• GIP — glucose-dependent insulinotropic polypeptide
• GLP-1 — glucagon-like peptide-1
• Glucagon

This triple-pathway activity makes retatrutide a significant area of current metabolic research.

Research Areas

Current research into retatrutide includes:

• Body-weight regulation — clinical trials have investigated its effects on body weight in adults with obesity or overweight.
• Appetite regulation — researchers are studying the interaction between GIP, GLP-1 and glucagon pathways and appetite.
• Glucose metabolism — research includes glucose and HbA1c-related outcomes.
• Energy metabolism — the combination of three hormonal pathways is being investigated for its effects on energy balance.
• Cardiometabolic research — studies are examining cardiovascular and metabolic markers.
• Lipid metabolism — research includes changes in cholesterol and triglyceride-related markers.
• Liver and metabolic disease research — retatrutide is being investigated in conditions including metabolic dysfunction-associated steatotic liver disease (MASLD).
• Type 2 diabetes research — Phase 3 studies have investigated retatrutide in adults with obesity/overweight and type 2 diabetes.

Investigational Status

Retatrutide is not currently approved by the FDA and remains an investigational medicine. Lilly states that it is currently being studied in Phase 3 clinical trials and that it is not available for public use outside those trials.

Storage & Handling

• Store refrigerated at 2–8°C.
• Do not freeze.
• Protect from direct sunlight and excessive heat.
• Keep out of reach of children and pets.
• Do not use if the product or packaging appears damaged or compromised.

For Research Purposes Only.